DK0625204T3 - Terapeutiske midler mod hepatitis - Google Patents

Terapeutiske midler mod hepatitis

Info

Publication number
DK0625204T3
DK0625204T3 DK93904901T DK93904901T DK0625204T3 DK 0625204 T3 DK0625204 T3 DK 0625204T3 DK 93904901 T DK93904901 T DK 93904901T DK 93904901 T DK93904901 T DK 93904901T DK 0625204 T3 DK0625204 T3 DK 0625204T3
Authority
DK
Denmark
Prior art keywords
hepatitis
therapeutic agents
infections
treating hepatitis
directs
Prior art date
Application number
DK93904901T
Other languages
English (en)
Inventor
Stephen M W Chang
Douglas J Jolly
William Tsung-Liang Lee
Kay Townsend
Joann O'dea
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25256972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0625204(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DK0625204T3 publication Critical patent/DK0625204T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Catching Or Destruction (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK93904901T 1992-02-04 1993-02-04 Terapeutiske midler mod hepatitis DK0625204T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83041792A 1992-02-04 1992-02-04
PCT/US1993/001009 WO1993015207A2 (en) 1992-02-04 1993-02-04 Hepatitis therapeutics

Publications (1)

Publication Number Publication Date
DK0625204T3 true DK0625204T3 (da) 2002-07-15

Family

ID=25256972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93904901T DK0625204T3 (da) 1992-02-04 1993-02-04 Terapeutiske midler mod hepatitis

Country Status (10)

Country Link
EP (1) EP0625204B1 (da)
JP (3) JPH07503615A (da)
AT (1) ATE219522T1 (da)
AU (2) AU3610293A (da)
CA (1) CA2128896A1 (da)
DE (1) DE69332045T2 (da)
DK (1) DK0625204T3 (da)
ES (1) ES2174845T3 (da)
PT (1) PT625204E (da)
WO (1) WO1993015207A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
ATE236981T1 (de) * 1993-11-04 2003-04-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
HUT77870A (hu) * 1994-10-05 1998-09-28 Apollon, Inc. Hepatitiszvírus elleni vakcinák
US5856169A (en) * 1995-02-21 1999-01-05 Thomas Jefferson University Isoforms of human interleukin-1β converting enzyme and methods of using the same
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
AU2800797A (en) 1996-04-05 1997-10-29 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
JP4474198B2 (ja) * 2004-05-19 2010-06-02 株式会社日立ハイテクノロジーズ C型肝炎ウイルス恒温増幅用プライマー
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP2680859B1 (en) * 2011-03-02 2022-04-27 Jerome Schentag Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751664T2 (de) * 1986-08-01 1996-06-05 Commw Scient Ind Res Org Rekombinanter impfstoff
WO1988006185A1 (en) * 1987-02-11 1988-08-25 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
AU7679491A (en) * 1990-04-04 1991-10-30 Protos, Inc. Hepatitis c virus protease inhibitors
HU217025B (hu) * 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
AU652941B2 (en) * 1990-06-25 1994-09-15 Research Foundation For Microbial Diseases Of Osaka University, The Non-A, Non-B hepatitis virus particles
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens

Also Published As

Publication number Publication date
ES2174845T3 (es) 2002-11-16
CA2128896A1 (en) 1993-08-05
AU3610293A (en) 1993-09-01
WO1993015207A3 (en) 1994-01-06
JPH07503615A (ja) 1995-04-20
DE69332045D1 (de) 2002-07-25
JP2003055265A (ja) 2003-02-26
EP0625204A1 (en) 1994-11-23
AU7530996A (en) 1997-02-20
DE69332045T2 (de) 2002-10-17
JP2000154152A (ja) 2000-06-06
PT625204E (pt) 2002-10-31
EP0625204B1 (en) 2002-06-19
ATE219522T1 (de) 2002-07-15
WO1993015207A2 (en) 1993-08-05

Similar Documents

Publication Publication Date Title
DK0625204T3 (da) Terapeutiske midler mod hepatitis
RU93058676A (ru) Оральное лечение геликобактерной инфекции
BR9712488A (pt) Anticorpo anti-hm 1.24 humano remodelado
LU88365I2 (fr) Hbvax vaccin recombinant contenant une protéine HBsAG pour une immunisation active contre des infections dues à l'hépatite B.
LU88364I2 (fr) HBVax Vaccin recombinant contenant une protéine HBsAG pour une immunisation active contre des infections dues à l'hépatite B.
ATE177755T1 (de) Hybrides protein zwischen cs aus plasmodium und hbsag
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
DK0992580T3 (da) Epitoper på human T-celler, som er immundominante for hepatitis C-virus
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
NO941310L (no) Sammensetning og fremgangsmåte for behandling av hepatitt C
ATE328099T1 (de) Inhibierung des wachstums von ausgewählten tumoren mit rekombinanten viren-vektoren
EP1150710A4 (en) IMMUNOGENOUS COMPLEXES AND METHODS RELATING TO THESE
CY1110533T1 (el) Μεθοδοι και σκευασματα για νοσους σχετιζομενες με την αμυλοειδωση
HUP9801242A1 (hu) Hepatitis B vakcina
DK0552240T3 (da) Ny metode til behandling af depression
ATE359089T1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus
EP0600396A3 (en) Gut protozoan vaccines.
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
ATE285791T1 (de) Impfstoff, der acemannan als adjuvans enthält
NO905301L (no) Malaria - vaksine.
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
NO172120C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoxazoler
GEP19991793B (en) Hepatitis C Virus (HCV) Polypeptides, Method for Obtaining the Same, Immunogenic Reagents, Method for Discovering Antibodies, Method for Induction of Immune Response